The registered use: hepatitis
Thymosin alpha-1's registered indication is chronic hepatitis B, and the Zadaxin label prescribes it as monotherapy: 1.…
A real but small, delayed, and inconsistent effect
Thymosin alpha-1's registered indication is chronic hepatitis B, and the Zadaxin label prescribes it as monotherapy: 1.6 mg subcutaneously twice a week for six months, in adults with compensated liver disease and detectable HBV DNA. Calling it an adjuvant is a fair verdict on what the evidence supports, but it is not what the label says. This is where its strongest clinical rationale lives, and also where the honest picture is most instructive: a foundational positive trial, a canonical delayed-response meta-analysis, and a negative phase III study, all at once.
This unit reads that evidence carefully: the Chien 1998 RCT, the Chan 2001 meta-analysis, the negative Mutchnick 1999 phase III trial, combination regimens, and why the hepatitis C role is now largely historical in the direct-acting-antiviral era.
Key terms
The foundational hepatitis B trial
The anchor study is the Chien 1998 randomized controlled trial in Taiwan, which compared Tα1 monotherapy against control in chronic hepatitis B. It reported a higher complete virologic response with a striking feature: the benefit emerged after treatment ended, a delayed response.
The delayed pattern is the interesting part. A benefit that grows after dosing stops fits an immune-mediated mechanism, the T-cell and dendritic-cell rebalancing from earlier units, rather than a direct antiviral hit. Low endogenous Tα1 levels reported in chronic HBV carriers were part of the original rationale.
AdvancedWhy a delayed response complicates interpretation
Most antivirals show their effect during dosing. A response that appears months after treatment is consistent with priming a durable immune response, but it also complicates trial design and interpretation: follow-up must be long, and the comparator's natural history over that window matters. The delayed-response signature is genuinely interesting and genuinely harder to prove cleanly, both at once.